See the DrugPatentWatch profile for polivy

After reviewing the available information, the most common adverse reactions to Polivy (generic name: polatuzumab vedotin-piiq) include [1]:

1. Neutropenia: This is a condition characterized by a lower-than-normal number of neutrophils, a type of white blood cell that helps fight infections [1].
2. Thrombocytopenia: This is a condition characterized by a lower-than-normal number of platelets, which are blood cells that help your body form clots to stop bleeding [1].
3. Anemia: This is a condition characterized by a lower-than-normal number of red blood cells or a lower-than-normal amount of hemoglobin in the blood [1].
4. Peripheral neuropathy: This is a condition characterized by damage to the nerves that connect the spinal cord and brain to the rest of the body, causing symptoms such as pain, numbness, or tingling in the hands and feet [1].
5. Fatigue: This is a feeling of extreme tiredness or lack of energy [1].
6. Diarrhea: This is a condition characterized by loose, watery stools [1].
7. Nausea: This is a feeling of sickness with an inclination to vomit [1].
8. Pyrexia: This is an abnormally high body temperature [1].
9. Upper respiratory tract infection: This is an infection that affects the parts of the body that are above the chest [1].

It is important to note that these adverse reactions may not occur in all patients who receive Polivy, and some patients may experience adverse reactions not listed above [1]. Patients should consult their healthcare provider for a complete list of potential adverse reactions and for any questions or concerns about their treatment [1].

Sources:
[1] <https://www.drugpatentwatch.com/drugs/polivy>